Cullinan Therapeutics, Inc.
CGEM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789972
In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $1.30B in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Cullinan Therapeutics, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 153 | 2 | 174 | +23 |
| Shares | 63.2M | 3.30M | 65.6M | +5.67M (+9.5%) |
| Value | $653.8M | $34.1M | $931.0M | +$311.3M (+50.2%) |
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (40)
Institutions that held Cullinan Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
Sold out (17)
Institutions that held Cullinan Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Two Sigma Advisers, LP | 129,809 | $1.34M |
| Squarepoint Ops LLC | 75,820 | $784.7K |
| Jacobs Levy Equity Management, Inc | 73,755 | $763.4K |
| NEOS Investment Management LLC | 37,519 | $388.3K |
| Aquatic Capital Management LLC | 30,923 | $320.1K |
| ExodusPoint Capital Management, LP | 30,487 | $315.5K |
| Quest Partners LLC | 28,950 | $299.6K |
| EntryPoint Capital, LLC | 23,788 | $246.2K |
| Fox Run Management, L.L.C. | 21,204 | $219.5K |
| Schonfeld Strategic Advisors LLC | 16,638 | $172.2K |
| D. E. Shaw & Co., Inc. | 14,365 | $148.7K |
| Compass Ion Advisors, LLC | 13,904 | $143.9K |
| Nano Cap New Millennium Growth Fund L P | 10,000 | $103.5K |
| Caitong International Asset Management Co., Ltd | 4,680 | $48.4K |
| Amalgamated Bank | 1,696 | $18.0K |
| Daiwa Securities Group Inc. | 218 | $2.00K |
| Clearstead Advisors, LLC | 4 | $42 |
Not filed for Q1 2026 yet (2)
Institutions that held Cullinan Therapeutics, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 3,298,504 | $34.1M |
| Comerica Bank | 66 | $683 |